Brain tumour clinical trial title

IceCAP-A Phase I trial of ipatasertib in combination with atezolizumab (Study ID: 37081)

Brain tumour type




This is a single centre, proof-of-concept phase I trial. The purpose of this study is to find out the side effects and safety of ipatasertib in combination with atezolizumab in patients with advanced solid tumours with PI3K pathway hyperactivation and to determine the most appropriate dose of this combination. In Part A of this study up to 12 patients with advanced solid tumours (Cohort A1)and 3 patients with resectable glioblastoma multiforme (GBM)(Cohort A2) will be treated with increasing doses of ipatasertib in combination with a fixed dose of enzalutamide(1200mg once daily). Once Part A has been completed the combination with the optimum safety and pharmacokinetic/pharmacodynamic profile will be taken forward to Part B of the study. Part B of the study will evaluate the optimized dose/schedule identified in Part A of the study in in specific subgroups of patients. The specific cohorts are as follows; Cohort B1-patients with solid tumours with hyperactivation of PI3K pathway(n=12), Cohort B2-patients with castrate-resistant prostate cancer with PTEN loss(n=12), Cohort B3-patients with glioblastoma (n=12) of which at least three (n=3) patients will have potentially resectable recurrent glioblastomas.

Date added: 12th January 2019

Open/Closed: Open

Trial ends: September 2020


Royal Marsden Hospital NHS Foundation Trust

Contact details

Dr Anna Zachariou :

Telephone: 02087224605

Find on Google maps »